All In Biotech

BLA 761388 · Genentech INC

Piasky

Crovalimab-Akkz · Intravenous · Complement C5 Inhibitor

NovelOrphan

CDER novel approval, Jun 20, 2024: To treat paroxysmal nocturnal hemoglobinuria

Last checked: Nov 20, 2026Latest source record: May 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jun 20, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

10

6 Phase 3, 0 recruiting

FAERS reports

121

115 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS PIASKY, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1) ] . Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of PIASKY, unless the risks of delaying therapy with PIASKY outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional guidance on the management...

What it is approved for

From the label in effect Nov 11, 2025.

PIASKY is indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg. PIASKY is a complement C5 inhibitor indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg ( 1 )

Mechanism: Crovalimab-akkz is a monoclonal antibody that specifically binds with high affinity to the complement protein C5, inhibiting its cleavage into C5a and C5b, preventing the formation of the membrane attack complex (MAC). Crovalimab-akkz inhibits terminal complement-mediated intravascular hemolysis in patients with PNH.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PIASKY · CROVALIMAB-AKKZ 340MG/2ML(170MG/ML) · INJECTABLE, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Crovalimab" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia21
  • type iii immune complex mediated reaction21
  • anaemia20
  • off label use15
  • haemolysis14
  • infection11
  • breakthrough haemolysis10
  • pneumonia10
  • hepatic function abnormal8
  • covid-197
  • haemoglobin decreased7
  • sepsis7

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202412
202554
202655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 11 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.